Literature DB >> 22570009

[Urticaria. Basic knowledge for the ENT specialist].

V Daut1, P Staubach, K Hörmann, L Klimek, O Pfaar.   

Abstract

Urticaria describes a heterogeneous group of diseases, whose cardinal symptoms are itching wheals. With a high life time prevalence of 25%, this disease is of major relevance, and the ENT specialist should be familiar with this disease. The most common type is spontaneous Urticaria in which the wheals seem to arise without provocation. Its subtypes are acute and chronic. The mechanism of wheal formation is the activation and degranulation of mast cells. However, the etiology of the wheals is multifaceted. In case of acute spontaneous urticaria, the underlying cause does not have to be verified. It is treated symptomatically by its self-limiting course of disease. The chronic spontaneous, less frequent form of urticaria is treated curatively by identification and elimination of underlying causes, such as autoimmune processes, intolerance to food additives and chronic infections. The chronic subtype can persist for years and thus has an extensive socioeconomic impact. This article overviews the clinical symptoms, diagnostic methods and therapeutic options for both acute spontaneous and chronic spontaneous urticaria, and refers to the current international EAACI/WAO and German DGAKI/DDG S3 guidelines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22570009     DOI: 10.1007/s00106-011-2467-9

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  15 in total

1.  [Urticaria update].

Authors:  B Wedi; T Zuberbier
Journal:  Hautarzt       Date:  2010-09       Impact factor: 0.751

2.  Omalizumab--an effective and safe treatment of therapy-resistant chronic spontaneous urticaria.

Authors:  A Groffik; H Mitzel-Kaoukhov; M Magerl; M Maurer; P Staubach
Journal:  Allergy       Date:  2010-09-07       Impact factor: 13.146

3.  The impact of chronic urticaria on the quality of life.

Authors:  B F O'Donnell; F Lawlor; J Simpson; M Morgan; M W Greaves
Journal:  Br J Dermatol       Date:  1997-02       Impact factor: 9.302

4.  Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria.

Authors:  Martin Metz; Sabine Altrichter; Elena Ardelean; Birgit Kessler; Karoline Krause; Markus Magerl; Frank Siebenhaar; Karsten Weller; Torsten Zuberbier; Marcus Maurer
Journal:  Int Arch Allergy Immunol       Date:  2010-08-24       Impact factor: 2.749

Review 5.  Life-threatening severe allergic reactions: urticaria, angioedema, and anaphylaxis.

Authors:  Jasna Lipozencić; Ronni Wolf
Journal:  Clin Dermatol       Date:  2005 Mar-Apr       Impact factor: 3.541

Review 6.  Tissue mast cells in health and disease.

Authors:  M R Parwaresch; H P Horny; K Lennert
Journal:  Pathol Res Pract       Date:  1985-03       Impact factor: 3.250

7.  [Chronic urticaria. Prevalence, course, prognostic factors and impact].

Authors:  K Weller; S Altrichter; E Ardelean; K Krause; M Magerl; M Metz; F Siebenhaar; M Maurer
Journal:  Hautarzt       Date:  2010-09       Impact factor: 0.751

Review 8.  [Relevance of food allergies and intolerance reactions as causes of urticaria].

Authors:  M Maurer; A Hanau; M Metz; M Magerl; P Staubach
Journal:  Hautarzt       Date:  2003-01-29       Impact factor: 0.751

9.  Mast cell-driven skin inflammation is impaired in the absence of sensory nerves.

Authors:  Frank Siebenhaar; Markus Magerl; Eva M J Peters; Sven Hendrix; Martin Metz; Marcus Maurer
Journal:  J Allergy Clin Immunol       Date:  2007-12-26       Impact factor: 10.793

10.  Urticaria: its history-based diagnosis and etiologically oriented treatment.

Authors:  Marcus Maurer; Jürgen Grabbe
Journal:  Dtsch Arztebl Int       Date:  2008-06-20       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.